Multi-Agent Portfolio

Digest de scouts: X/opportunity scanner + top holdings 13F + news. Lo consume el consejo (Sentiment/Quant/Fundamental → Risk → PM) en el postmarket.

# MAP Sources Digest — 2026-09-01

_Generated 2026-09-01T20:15:34.008519+00:00_

## 1) Opportunity / X scanner

- Scan: `2026-08-31` · ideas=5 · rejected=19

### Ideas (passed filters)
- **ESTC** — Según el discurso en X, Elastic entregó FQ1 beat con demanda de AI search y follow-through el viernes (+19.3%, +16.3% semanal); Oppenheimer subió PT a $118 y el consenso lo rankea entre los mejores setups post-earnings del software.
- **S** — Según el discurso en X, SentinelOne post-earnings muestra ola de PT raises (Needham/Stephens/Scotiabank/Canaccord/Jefferies a $25-26) y pullback técnico que re-testa la EMA10; nivel clave $21.50-22, RS ~88.
- **GAP** — Según el discurso en X, Gap saltó ~13% con resultados mixtos por el anuncio de nuevo CEO para Old Navy, rompiendo una base de 2+ años con características de breakout mensual.
- **ZETA** — Según el discurso en X, Zeta Global se compara favorablemente vs APP (27x fwd P/E con 40%+ growth) y el nuevo segmento Zeta Business Intelligence expande la tesis más allá de ads; sin noticias frescas el finde.
- **KOD** — Según el discurso en X, Kodiak tiene topline de Ph3 DAYBREAK en septiembre (fecha TBC) para KSI-501/Zenkuda en wet AMD (~690 pacientes); uno de los binarios clínicos más seguidos del mes.

### X discourse — top rejected (still useful signal)
- **CMPS** (-1.6% 1d / -4.86% 5d) — Según el discurso en X, Compass Pathways tiene 2 wins de Ph3 con COMP360 (psilocibina, TRD), NDA apuntado a Q4-2026 con rolling review y launch potencial H1-2027; cash ~$433M hasta 2028 y read-through del deal Lilly-AtaiBeckley.
  - catalysts: 2 Ph3 wins (COMP360 en depresión resistente a tratamiento); NDA Q4-2026, launch H1-2027 posible, Cash ~$433M hasta 2028; upgrades B. Riley $22 / MS $18; sector validation Lilly-AtaiBeckley $2.8B
  - rejected: volume_ratio_below_0.8 (0.64)
  - risks: Binario regulatorio/NDA; biotech de alta volatilidad; el pullback reciente fue por risk-off macro.
- **ANF** (-3.6% 1d / 27.34% 5d) — Según el discurso en X, Abercrombie rompió una base de ~1.5 años con Q2 blowout (+39% semanal, casi 10x volumen) y se destaca como uno de los setups Stage 2 más fuertes fuera de AI, con valuación razonable (~12x fwd).
  - catalysts: Q2 blowout + outlook fuerte; +39% semanal con ~10x volumen y breakout de base larga, Valuación ~12x fwd earnings con momentum (rare combo, ~$6.5B mcap)
  - rejected: extended_chase (dist_ma20=22.15%, day=-3.6%)
  - risks: Extensión post-earnings (dist MA20 ~29% el viernes); consumo discrecional sensible a tasas.
- **CYTK** (-1.64% 1d / -8.02% 5d) — Según el discurso en X, Cytokinetics presentó en ESC 2026 datos positivos de ACACIA-HCM (no-obstructiva) y MAPLE-HCM (aficamten vs metoprolol) con mejoras de estructura cardíaca; FDA submission planeada Q4-2026 y más catalysts de label expansion en 12 meses.
  - catalysts: Ph3 ACACIA-HCM positivo (ESC 2026): mejora de estructura/función diastólica en HCM no-obstructiva, MAPLE-HCM: aficamten superó a metoprolol; FDA submission Q4-2026
  - rejected: structure_breakdown
  - risks: Debate de seguridad (edema/síntomas de heart failure en un subgrupo, preguntas de Cantor); comercialización pendiente.
- **PGY** (-1.09% 1d / -0.37% 5d) — Según el discurso en X, Pagaya no tuvo buzz fresco en el finde; la tesis sigue siendo el Q2 ($45M net income, guía raised del 27-ago) sin confirmación nueva.
  - catalysts: Q2: net income $45M + guía FY raised (27-ago); +21% en el print
  - rejected: volume_ratio_below_0.8 (0.57)
  - risks: Sin noticias frescas desde el 27-ago (decay); vol flojo (0.68x el viernes); auto-lending sensible a tasas.
- **SRRK** (-1.73% 1d / -2.41% 5d) — Según el discurso en X, Scholar Rock tiene PDUFA el 30-sept para apitegromab en SMA; el tema de manufactura de Catalent Indiana (OAI) se habría resuelto sumando una segunda planta fill-finish.
  - catalysts: PDUFA 30-sept: apitegromab en atrofia muscular espinal, Fill-finish alternativo activo tras issues de Catalent (OAI)
  - rejected: final_score_below_0.55
  - risks: Binario regulatorio; la manufactura sigue siendo el riesgo residual del dossier.
- **ABVX** (-1.43% 1d / -3.81% 5d) — Según el discurso en X, Abivax defiende su Ph3 de obefazimod en UC con datos de remisión/endoscopia fuertes vs competencia y pico de ventas debatido ($2.5-4B); NDA apuntado a fin de 2026, con spec de M&A a $22-25B en algunos posts.
  - catalysts: Ph3 obefazimod (UC) positivo; NDA year-end 2026; pre-NDA meeting 30-jul, Leerink pico IBD ~$4B; Truist ~$2.5B UC; spec de interés estratégico
  - rejected: structure_breakdown
  - risks: Crohn's no está garantizado (data mid-2027, timeline 2030-32); el stock viene underperforming; pico de ventas es debate, no hecho.
- **IREN** (4.7% 1d / -6.77% 5d) — Según el discurso en X, IREN pivotea a AI/cloud con ~$4B ARR contratado para 2026 y spec de Anthropic como anchor tenant (S-1 post-Labor Day), con PTs $78-100 (Bernstein $100, Cantor $99); el Q4 vendió -15% por impairments de mining y capex.
  - catalysts: ~$4B ARR contratado de AI cloud 2026 (50MW B300 Childress); spec Anthropic como tenant, PTs 12m: Bernstein $100, Cantor $99, consenso ~$78 vs precio ~$35
  - rejected: structure_breakdown
  - risks: Dilución severa para capex (shares 283M→394M); impairments; la tesis depende de un contrato no revelado y del sentimiento AI infra.
- **TENB** (1.27% 1d / 12.4% 5d) — Según el discurso en X, Tenable entra al S&P SmallCap 600 EFECTIVO hoy (reemplaza a LEG, compras pasivas) y el chart aparece en listas de strong setups; el catalizador mecánico se consume hoy.
  - catalysts: Add al S&P SmallCap 600 efectivo 31-ago (flujos de rebalanceo; LEG reemplazado), Setup técnico limpio en strong-setups lists para esta semana
  - rejected: final_score_below_0.55
  - risks: Post-index fade: el flujo pasivo ya fue anticipado (fue idea 28 y 29-ago); valuación ~79x cash earnings.

## 2) 13F top holdings (latest filing on disk)

### Berkshire — filing 2026-08-14 · 29 names
- APPLE INC: $65.95B (22.04%)
- AMERICAN EXPRESS CO: $51.282B (17.14%)
- COCA COLA CO: $32.508B (10.86%)
- ALPHABET INC: $28.158B (9.41%)
- BANK OF AMER CORP: $27.544B (9.2%)
- CHEVRON CORPORATION: $13.986B (4.67%)
- OCCIDENTAL PETE CORP: $12.868B (4.3%)
- CHUBB LIMITED: $11.67B (3.9%)

### Pershing Square — filing 2026-05-15 · 11 names
- BROOKFIELD CORP: $2.416B (17.62%)
- AMAZON COM INC: $2.385B (17.39%)
- UBER TECHNOLOGIES INC: $2.155B (15.71%)
- MICROSOFT CORP: $2.093B (15.26%)
- RESTAURANT BRANDS INTL INC: $1.674B (12.2%)
- META PLATFORMS INC: $1.522B (11.1%)
- HOWARD HUGHES HOLDINGS INC: $1.193B (8.7%)
- SEAPORT ENTMT GROUP INC: $0.108B (0.79%)

### Scion/Burry — filing 2025-11-03 · 8 names
- PALANTIR TECHNOLOGIES INC: $0.912B (66.04%)
- NVIDIA CORPORATION: $0.187B (13.51%)
- PFIZER INC: $0.153B (11.07%)
- HALLIBURTON CO: $0.061B (4.45%)
- MOLINA HEALTHCARE INC: $0.024B (1.73%)
- LULULEMON ATHLETICA INC: $0.018B (1.29%)
- SLM CORP: $0.013B (0.96%)
- BRUKER CORP: $0.013B (0.95%)

### Appaloosa — filing 2026-08-14 · 27 names
- AMAZON COM INC: $1.192B (15.43%)
- MICRON TECHNOLOGY INC: $1.125B (14.57%)
- TAIWAN SEMICONDUCTOR MANUFAC: $0.788B (10.2%)
- ALPHABET INC: $0.654B (8.46%)
- UBER TECHNOLOGIES INC: $0.555B (7.19%)
- ISHARES INC: $0.49B (6.34%)
- META PLATFORMS INC: $0.38B (4.92%)
- VISTRA CORP: $0.351B (4.55%)

### ARK — filing 2026-08-14 · 191 names
- Tesla Inc: $1.161B (7.54%)
- Advanced Micro Devices Inc: $0.823B (5.34%)
- Space Exploration Technologies Corp: $0.765B (4.97%)
- Tempus AI Inc: $0.581B (3.77%)
- Robinhood Markets Inc: $0.525B (3.41%)
- CRISPR Therapeutics AG: $0.516B (3.35%)
- Shopify Inc: $0.475B (3.08%)
- Twist Bioscience Corp: $0.468B (3.04%)

### Tiger Global — filing 2026-08-14 · 46 names
- TAIWAN SEMICONDUCTOR MANUFAC: $2.331B (9.72%)
- AMAZON COM INC: $2.308B (9.62%)
- NVIDIA CORPORATION: $2.241B (9.34%)
- ALPHABET INC: $2.075B (8.65%)
- META PLATFORMS INC: $1.59B (6.63%)
- LAM RESEARCH CORP: $1.371B (5.72%)
- SEA LTD: $1.204B (5.02%)
- APPLIED MATLS INC: $1.18B (4.92%)

## 3) News (yfinance / map_research)

- SPY $761.78 · 5d -0.56% (H 775.3 / L 759.48)

### MSFT
- Nvidia makes its biggest investment abroad with Mediatek: Why it's a uniquely important deal (Yahoo Finance Video, 2026-09-01)
- Software Stocks Just Did Something They've Done Only Three Times Before (GuruFocus.com, 2026-09-01)
- Microsoft's AI strategy accelerates cloud growth and efficiency: analysts (Proactive, 2026-09-01)

### GOOGL
- Two deals, one Nvidia strategy: What's behind the chip giant's recent partnerships (Yahoo Finance Video, 2026-09-01)
- Alphabet Drops as Google Signs 396-Megawatt Geothermal Deal (GuruFocus.com, 2026-09-01)
- Meta Is Catching Google in Ads. Which Stock Does Wall Street Favor? (BeInCrypto, 2026-09-01)

### AMZN
- Best student credit cards (2026): Start building credit with rewards on spending (Yahoo Personal Finance, 2024-09-12)
- Nvidia makes its biggest investment abroad with Mediatek: Why it's a uniquely important deal (Yahoo Finance Video, 2026-09-01)
- Amazon Stock Drops 4.6% as FTC Alleges More Than $20 Billion in Ad Overcharges (GuruFocus.com, 2026-09-01)

### JPM
- JPMorgan Rises as 10-Year Treasury Yield Hits 4.8% (GuruFocus.com, 2026-09-01)
- Morgan Stanley Stock Is Up Nearly 20% in 2026: What Will It Take to Break Through $250? (24/7 Wall St., 2026-09-01)
- Chamath Palihapitiya Says ‘Trust the Experts’ Approach To AI Is a Trap, Warns it Could Make COVID ‘Pale in Comparison’ (Benzinga, 2026-09-01)

### LLY
- This New Zepbound Study Could Be Great News for Eli Lilly Investors (Motley Fool, 2026-09-01)
- Novo Nordisk Trades Nearly 58% Below GF Value as Wegovy Pill Launches in Germany (GuruFocus.com, 2026-09-01)
- Eli Lilly to Buy Immunology Biotech Merida Biosciences in $2.9B Deal (Zacks, 2026-09-01)

### BRK-B
- Berkshire CEO Abel to Make Rare TV Appearance. What He Might Talk About. (Barrons.com, 2026-09-01)
- 3 Ways Warren Buffett Utilizes Patience Over Profit When Investing (MoneyLion, 2026-09-01)
- Greg Abel Thinks Berkshire's Stock Is Cheap -- Is He Right? Here's the Math. (Motley Fool, 2026-09-01)

### XOM
- Trump to meet with oil executives on lowering gas prices — and Exxon isn't invited (Yahoo Finance Video, 2026-09-01)
- Sector Update: Energy Stocks Rise Late Afternoon (MT Newswires, 2026-09-01)
- Energy ETFs to Watch as US-Venezuela Sign Historic Oil Deal (Zacks, 2026-09-01)

### V
- Can you use a credit card on Venmo? (Yahoo Personal Finance, 2024-01-26)
- Bank of England governor warns AI could trigger global downturn (Yahoo Finance Video, 2026-08-31)
- Ethena Launches Neobank App on Avalanche (Bankless, 2026-09-01)

### ZYME
- JAZZ Rises on Updated OS Results From Gastric Cancer Study (Zacks, 2026-09-01)
- Zymeworks (ZYME), What Is Behind The Renewed Attention? (Simply Wall St., 2026-08-28)
- Is Zymeworks (ZYME) Stock Fully Priced After Its 301% Run? (Simply Wall St., 2026-08-28)

### SPY
- Target Stock Is Up 66% in 2026: What Will It Take to Break Through $200? (24/7 Wall St., 2026-09-01)
- Morgan Stanley Stock Is Up Nearly 20% in 2026: What Will It Take to Break Through $250? (24/7 Wall St., 2026-09-01)
- Wars May Rattle Markets at First, But This Wealth Manager Says the S&P 500 Has Historically Turned Conflict Into a Long-Term ‘Boost for Asset Owners’ (Benzinga, 2026-09-01)

## Cómo usar esto (Bull / Bear / PM)

- Bull: priorizá catalysts de la sección X + news alineados a momentum USA.
- Bear: usá reasons_rejected + risks + concentración 13F como veto/overcrowding.
- PM: no copies 13F ciegamente; es contexto, no orden.